Synthesis of Some New Tetrahydropyrimidine Derivatives as Possible Antibacterial Agents

Naser Foroughifar, Somayeh Karimi Beromi, Hoda Pasdar and Masoumeh Shahi

*Department of Chemistry, Tehran North Branch, Islamic Azad University, Tehran, Iran.

Abstract

Heterocyclic compounds containing a pyrimidine nucleus are of special interests thanks to their applications in medicinal chemistry as they are the basic skeleton of several bioactive compounds such as antifungal, antibacterial, antitumor and antitubercular. As a part of our research in the synthesis of pyrimidine derivatives containing biological activities, some new tetrahydropyrimidine derivatives (1-10) were synthesized via Biginelli reaction using HCl or DABCO as a catalyst with good yields. All structures of products were confirmed by IR, 1H NMR and 13C NMR spectroscopy. The antibacterial activity of some synthesized compounds was investigated against *Staphylococcus aureus* (ATCC 6538), *Staphylococcus epidermidis* (ATCC 12228), *Bacillus cereus* (ATCC14579), *Esherichia coli* (ATCC 25922), *Klebsiella pneumonia* (ATCC 13883) and *Pseudomonas aeruginosa* (PAO1) bacteria. Some of these compounds such as 8 and 10 exhibited a good to significant antibacterial activity.

Keywords: tetrahydropyrimidine; antimicrobial activity; Biginelli reaction.

Introduction

Tetrahydropyrimidines and their derivatives have recently attracted considerable interest thanks to their pharmacological activities such as anticancer (1), antiviral (2), calcium channel modulation (3) and antibacterial activity (4-6). The Biginelli reaction is one of the simple and direct methods for the synthesis of tetrahydropyrimidines, originally reported by Biginelli (7). Regarding the importance of the Biginelli reaction products, much work on improving the yield and reaction conditions has been actively pursued. For example, using Lewis acids as a catalyst such as Cu(OTf)₃ (8), Yb(OTf)₃ (9), Triethylammonium hydrogen sulfate (10), BiCl₃ (11) and Mn(OAc)₃·2H₂O (12) instead of acidic reagents significantly improved the reaction output with reduced reaction times. The polymer-supported, resin-bound isothiourea (13), polymer nanocomposite (14) and various other catalysts (15, 16) have been used for synthesis of Biginelli products. In general terms, this report is going to describe the synthesis of new tetrahydropyrimidine derivatives via the Biginelli reaction using HCl or DABCO as a catalyst in ethanol. Biological activities of synthesis compounds were tested against gram-positive and gram-negative bacteria.

Experimental

Melting points were determined with an Electrothermal digital apparatus and were uncorrected. IR spectra were obtained on a Galaxy Series FT-IR 5000 spectrophotometer in KBr. NMR spectra were recorded on a Brucker 500 and 300 MHz spectrometer, chemical shifts were given in ppm in DMSO-d₆ using TMS as an internal standard.
General procedure for synthesis of tetrahydropyrimidine derivatives (1-10)

A mixture of an ethyl benzoyleacetate (1 mmol), aromatic aldehyde (1 mmol), thiourea (1 mmol) and an amount of concentration Hydrochloric acid or DABCO (0.1 mmol) in ethanol (15 mL) were heated under reflux for an appropriate time (Table 3). The progress of the reaction was monitored by TLC (Thin-Layer Chromatography) using water-ethanol (1:1) as an eluent and after competition, the reaction mixture was cooled at room temperature. The remaining solid was filtered, washed with water and ethanol and it was consequently dried and recrystallized using ethanol.

5-Ethoxycarbonyl-4,6-diphenyl-1,2,3,4-tetrahydropyrimidine-2-thione (1): IR (KBr) ν_max (cm⁻¹): 3386 (NH), 3365 and 2937 (CH), 1676 (C=O), 1567 (C=S), 1369 (C=C) and 1336 (C-O).

1H NMR (DMSO-d₆) δ ppm: 10.53 (s, 1H, NH); 9.80 (s, 1H, NH); 7.14-7.43 (m, 10H, Ar-H); 5.27 (s, 1H, H(4)); 3.71-3.79 (q, J=7.5 Hz, 2H, CH₂) and 0.71-0.76 (t, J=7.5 Hz, 3H, CH₃).

13C NMR (DMSO-d₆) δ ppm: 13.36, 54.09, 59.51, 101.77, 126.43, 127.74, 127.86, 128.70, 128.74, 129.16, 134.00, 145.90, 164.92 and 174.50.

5-Ethoxycarbonyl-4-(4-chlorophenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidine-2-thione (2): IR (KBr) ν_max (cm⁻¹): 3304 (NH), 3158 and 2981 (CH), 1735 (C=O), 1589 (C=S), 1469 (C=C), 1432 (C-O) and 724 (C-Cl).

1H NMR (DMSO-d₆) δ ppm: 10.71 (s, 1H, NH); 9.90 (s, 1H, NH); 7.38-8.22 (m, 9H, Ar-H); 5.41 (s, 1H, H(4)); 3.71-3.78 (q, J=7.0 Hz, 2H, CH₂) and 0.70-0.74 (t, J=7.0 Hz, 3H, CH₃).

13C NMR (DMSO-d₆) δ ppm: 13.33, 53.44, 59.71, 100.86, 121.21, 122.92, 127.81, 128.71, 129.39, 130.63, 133.07, 133.66, 144.99, 146.75, 149.11, 165.95 and 175.17.

5-Ethoxycarbonyl-4-(3,4-dimethoxyphenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidine-2-thione (3): IR (KBr) ν_max (cm⁻¹): 3415 (NH), 3060 and 2925 (CH), 1735 (C=O), 1570 (C=S), 1493 (C=C), 1455 (C-O) and 1291 (C-C).

1H NMR (DMSO-d₆) δ ppm: 10.48 (s, 1H, NH); 9.74 (s, 1H, NH); 6.87-7.43 (m, 8H, Ar-H); 5.22 (s, 1H, H(4)); 3.75-3.80 (q, J=7.1 Hz, 2H, CH₂); 3.73, 3.71 (both s, 3H each, 2 O-CH₃) and 0.73-0.78 (t, J=7.2 Hz, 3H, CH₃).

13C NMR (DMSO-d₆) δ ppm: 13.80, 54.11, 55.85, 59.88, 102.33, 110.83, 121.21, 122.92, 127.81, 128.71, 129.39, 130.63, 133.07, 133.66, 144.99, 146.75, 149.11, 165.34 and 174.81.

5-Ethoxycarbonyl-4-(4-methoxyphenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidine-2-thione (4): IR (KBr) ν_max (cm⁻¹): 3165 (NH), 2975 and 2836 (CH), 1694 (C=O), 1599 (C=S), 1463 (C=C), 1368 (C-O) and 1249 (C-C).

1H NMR (DMSO-d₆) δ ppm: 10.42 (s, 1H, NH); 9.87 (s, 1H, NH); 6.65-7.96 (m, 9H, Ar-H); 5.22 (s, 1H, H(4)); 3.74 (s, 3H, O-CH₃); 3.87-3.71 (q, J=7.1 Hz, 2H, CH₂) and 0.71-0.74 (t, J=7.1 Hz, 3H, CH₃).

13C NMR (DMSO-d₆) δ ppm: 14.21, 54.11, 55.99, 60.30, 102.97, 114.88, 128.54, 128.56, 129.00, 129.50, 130.52, 132.67, 134.94, 136.41, 159.17, 165.78 and 175.17.

5-Ethoxycarbonyl-4-(4-methylphenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidine-2-thione (5): IR (KBr) ν_max (cm⁻¹): 3367 (NH), 3108 and 2975 (CH), 1698 (C=O), 1571 (C=S), 1464 (C=C), 1260 (C-O) and 1097 (C-C).

1H NMR (DMSO-d₆) δ ppm: 9.70 (s, 1H, NH); 6.86-7.29 (m, 9H, Ar-H); 5.21 (s, 1H, H(4)); 3.69-3.78 (q, J=7.1 Hz, 2H, CH₂) and 2.28 (s, 3H, C(4)-p-CH₃-Phenyl) and 0.69-0.74 (t, J=7.1 Hz, 3H, CH₃).

5-Ethoxycarbonyl-4-(3-nitrophenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidine-2-thione (6): IR (KBr) ν_max (cm⁻¹): 3421 (NH), 3060 and 2927 (CH), 1727 (C=O), 1583 (C=S), 1476 (C=C), 1445 (C-O) and 1293 (C-C).

1H NMR (DMSO-d₆) δ ppm: 8.35 (s, 1H, NH); 7.51-7.92 (m, 9H, Ar-H); 5.51 (s, 1H, H(4)); 3.57-3.30 (q, J=7.1 Hz, 2H, CH₂) and 0.98-1.03 (t, J=7.1 Hz, 3H, CH₃).

5-Ethoxycarbonyl-4-(2-hydroxyphenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidine-2-thione (7): IR (KBr) ν_max (cm⁻¹): 3381 (NH), 3089 and 2983 (CH), 1693 (C=O), 1580 (C=S), 1491 (C=C), 1459 (C-O) and 1260 (C-C).

1H NMR (DMSO-d₆) δ ppm: 12.25 (s, 1H, OH); 8.55 (s, 1H, NH); 8.26 (s, 1H, NH); 7.51-8.21 (m, 9H, Ar-H).
Ar-H); 5.70 (s, 1H, H(4)); 3.54-3.31 (q, J=7.2 Hz, 2H, CH₂) and 0.78-0.93 (t, J=7.1 Hz, 3H, CH₃).

5-Ethoxycarbonyl-4-(5-bromo-2-hydroxyphenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidine-2-thione (8): IR (KBr) ν_max (cm⁻¹): 3526 (OH), 3304 (NH), 3166 and 2978 (CH), 1723 (C=O), 1576 (C=S), 1489 (C=C), 1394 (C-O), 1289 (C-C) and 823 (C-Br). ¹H NMR (DMSO-d₆) δ ppm: 10.19 (s, 1H, OH); 7.68 (s, 1H, NH); 7.62 (s, 1H, NH); 6.93-7.63 (m, 8H, Ar-H); 5.25 (s, 1H, H(4)); 3.67-3.70 (q, J=7.1 Hz, 2H, CH₂) and 0.95-1.01 (t, J=7.0 Hz, 3H, CH₃).

5-Ethoxycarbonyl-4-(4-isopropylphenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidine-2-thione (9): IR (KBr) ν_max (cm⁻¹): 3422 (NH), 3186 and 2925 (CH), 1629 (C=O), 1484 (C=S), 1386 (C=C), 1245 (C-O) and 1081 (C-C). ¹H NMR (DMSO-d₆) δ ppm: 10.49 (s, 1H, NH); 9.75 (s, 1H, NH); 7.29-7.43 (m, 9H, Ar-H); 5.23 (s, 1H, H(4)); 3.37-3.79 (q, J=7.5 Hz, 2H, CH₂), 1.19-1.22 (m, 7H, H iPr) and 0.70-0.79 (t, J=7.5 Hz, 3H, CH₃).

5-Ethoxycarbonyl-4-(4-hydroxyphenyl)-6-phenyl-1,2,3,4-tetrahydropyrimidine-2-thione (10): IR (KBr) ν_max (cm⁻¹): 3489 (OH), 3318 (NH), 3178 and 3000 (CH), 1683 (C=O), 1566 (C=S), 1462 (C=C), 1370 (C-O) and 1333 (C-C).

Antibacterial Activity
To examine the antibacterial activity of some synthesized compounds, three gram negative bacteria: *Escherichia coli* (ATCC 25922), *Klebsiella pneumoniae* (ATCC 13883) and *Pseudomonas aeruginosa* (PAO1) and three gram positive bacteria: *Staphylococcus aureus* (ATCC 6538), *Staphylococcus epidermidis* (ATCC 12228), *Bacillus cereus* (ATCC 14579) were selected and tested by the disc diffusion method (17) using Mueller–Hinton agar against. Normal saline was used as the standard. Normal saline was used for preparation of inoculants having turbidity equal to 0.5 McFarland standards. Tested compounds were dissolved in dimethyl sulfoxide (DMSO) for the preparation of stock solution. The solvent control was included, although no antibacterial activity has been noted. Culture was carried out with sterile swab and microtome suspension was cultured for 24 h and then inoculated onto Mueller–Hinton agar. Blank discs with a diameter of 6 mm and containing 30 μg of the concentration of these compounds (1-10) were placed on Muller Hinton agar medium. After 24 h incubation at 37 °C, zones of growth inhibition were measured. Disks containing 10 μg of dimethyl sulfoxide were used as the negative control. Each concentration was repeated 4 times for each of the bacteria and the average results of inhibitory effects are illustrated in Table 1.

Determination of the minimum inhibitory concentration (MIC) values for some synthesized compounds against six microorganisms was carried out using disc diffusion method (18). In this method, concentration of 10, 20, 30, 50, …….., 150 μg/mL were used for all bacteria per disc and there were incubated at 37 °C for 24 h. MIC value was defined as lowest concentration of compound for inhibition growth of the tested bacteria. The results are shown in Table 2.

Results and Discussion
The benzaldehyde derivatives with substitution in aromatic ring with 4-chloro, 3,4-dimethox, 4-methoxy, 3-nitro, 2-hydroxy, 5-bromo-2-hydroxy, 4-isopropyl and 4-hydroxy groups were reacted with thiourea and ethyl benzoylacetate in the presence of HCl or DABCO as a catalyst under reflux condition to prepare a series of tetrahydropyrimidine derivatives 1-10 (scheme1, Table 3). According to Table 3, the best results were obtained in the presence of DABCO as a catalyst where the products were achieved with high yields and shorter reaction times.

The IR spectra of tetrahydropyrimidine derivatives 1-10 exhibited absorption bands at 1570 and 1590 cm⁻¹ relating to C=S and C=O, respectively. The broad absorption band for stretching vibration of NH groups was detected in the region 3100-3360 cm⁻¹. In ¹H NMR spectra, all of the products 1-10 showed a singlet peak at about 5.2-5.4 ppm for H-4. Two singlet peaks for NH groups in pyrimidine ring were observed at about 10.4-10.7 and 9.7-9.9 ppm,
Synthesis of biologically active tetrahydropyrimidine derivatives

which disappearing upon D₂O addition. The
¹³C NMR spectra of these compounds showed a
signal at about 164.8-165.7 for C=S and a signal
at about 174.5-175.1 ppm for C=O group.

Antibacterial activities of compounds 1-4, 6 and 8-10 were measured on three gram
negative bacteria (E. coli, K. pneumoniae and P. aeruginosa) and three gram positive bacteria
(S. aureus, S. epidermidis and B. cereus) by disc
diffusion method and the minimum inhibitory
concentration (MIC) in-vitro. Cephalexin
was used as the standard antibacterial agent.

The results of bioassay are given in Tables 1
and 2. As shown in Table 2, these compounds
exhibited good inhibitory activity against
S. aureus with MIC values about 15-45 µg/

Table 3. Characterization data of tetrahydropyrimidine derivatives 1-10.

| Comp. No | Yields (%) | Time (h) | m.p. (°C) | Catalyzed by DABCO | Catalyzed by HCl |
|----------|------------|----------|-----------|--------------------|-----------------|
| 1        |            |          | 197-200   | 70                 | 45              |
| 2        |            |          | 178-180   | 72                 | 63              |
| 3        |            |          | 213-216   | 81                 | 63              |
| 4        |            |          | 202-204   | 81                 | 63              |
| 5        |            |          | 179-182   | 88                 | 50              |
| 6        |            |          | 226-228   | 71                 | 52              |
| 7        |            |          | 243-245   | 81                 | 50              |
| 8        |            |          | 127-129   | 79                 | 50              |
| 9        |            |          | 211-213   | 70                 | 62              |
| 10       |            |          | 218-220   | 74                 | 54              |

*Reported yields are after recrystallization

Scheme 1. The synthetic pathway for preparation of tetrahydropyrimidine derivatives 1-10

Table 1. Antibacterial activity of some synthesized compounds (inhibition zones, mm).

| Comp. No | S. aureus | S. epidermidis | Bacillus cereus | K. pneumoniae | E. Coli | P. aeruginosa |
|----------|-----------|---------------|----------------|---------------|---------|--------------|
| 1        | 20        | -             | -              | -             | -       | -            |
| 2        | 15        | 30            | -              | -             | -       | 15           |
| 3        | 14        | 18            | -              | -             | -       | -            |
| 4        | 10        | 18            | -              | -             | -       | 5            |
| 6        | 15        | -             | 10             | -             | -       | -            |
| 8        | 45        | 58            | 32             | 45            | 39      | 50           |
| 9        | 15        | 25            | -              | -             | -       | -            |
| 10       | 14        | 22            | mutation       | 15            | -       | -            |
| Cephalexin* | 34  | 35            | -              | 29            | 26      | -            |

*Dimethyl sulfoxide (DMSO) only, control for compounds and references.
*Reference compound
Table 2. MIC values of some synthesized compounds.

| Comp. No | MIC (μg.mL⁻¹) | S. aureus | S. epidermidis | Bacillus cereus | K. pneumoniae | E. Coli | P. aeruginosa |
|----------|---------------|-----------|----------------|----------------|---------------|--------|-------------|
| 1        | 37            | 25        | NP             | 95             | 120           | 100    |             |
| 2        | 45            | 25        | 20             | 100            | 120           | 50     |             |
| 3        | 45            | 95        | NP             | 100            | NP            | 50     |             |
| 4        | 20            | 15        | 100            | 100            | 120           |        |             |
| 5        | 45            | 80        | NP             | 50             | 120           |        |             |
| 6        | 15            | 15        | 15             | 15             | 15            | 70     |             |
| 7        | 45            | 30        | NP             | 95             | 110           | 70     |             |
| 8        | 45            | 15        | NP             | 50             | 110           | NP     |             |
| 9        | 45            | 15        | 50             | 23             | 15            | 46     |             |

Cephalexin*  
NP: not performed  
*Reference compound

Table 3. Characterization data of tetrahydropyrimidine derivatives 1-10.

| Product | Ar               | Time (h) | Yield (%)* | Yield (%)* | Yield (%)* | Yield (%)* | m.p (ºC) |
|---------|------------------|----------|------------|------------|------------|------------|----------|
|         |                  | Catalyzed by HCl | Catalyzed by DABCO | Catalyzed by HCl | Catalyzed by DABCO | m.p (ºC) |
| 1       | C₂H₅             | 7        | 4          | 45         | 70         | 197-200    |
| 2       | 4-Cl-C₆H₄        | 7        | 5          | 63         | 72         | 178-180    |
| 3       | 3,4-OMe-C₆H₄     | 7        | 3          | 63         | 81         | 213-216    |
| 4       | 4-OMe-C₆H₄       | 7        | 3          | 63         | 81         | 202-204    |
| 5       | 4-Me-C₆H₄        | 7        | 4          | 53         | 88         | 179-182    |
| 6       | 3-NO₂-C₆H₄       | 7        | 4          | 52         | 71         | 226-228    |
| 7       | 2-OH-C₆H₄        | 7        | 3          | 50         | 81         | 243-245    |
| 8       | 5-Br-2-OH-C₆H₄   | 7        | 4          | 50         | 79         | 127-129    |
| 9       | 4-ipr-C₂H₅       | 7        | 4          | 62         | 70         | 211-213    |
| 10      | 4-OH-C₂H₅        | 7        | 3          | 54         | 74         | 218-220    |

*Reported yields are after recrystallization

inhibitory activity (15-25 μg/mL) against all organism tests, in comparison to Cephalexin which is a well-known antimicrobial drug.

References

(1) Ghorab MM, Adel-Gaward SM and El-Gaby MSA.
(2) Kappe CO. Biologically active dihydropyrimidones of the Biginelli-type — a literature survey. Eur. J. Med. Chem. (2000) 35: 1043-1052.
(3) Atwal KS, Rovnyk GCO, Reilly BC and Schwartz J. Substituted 1,4-dihydropyrimidines. 3. Synthesis of selectively functionalized 2-hetero-1,4-
Synthesis of biologically active tetrahydropyrimidine derivatives

(4) Mobinikhaledi A, Foroughifar N, Mosleh T and Hamta A. Synthesis of some novel chromenopyrimidine derivatives and evaluation of their biological activities. *Iran. J. Pharm. Res.* (2014) 13: 873-879.

(5) Kappe CO. 100 Years of the Biginelli dihydropyrimidine synthesis. *Tetrahedron* (1993) 49: 6937-6963.

(6) Shahi M, Foroughifar N and Mobinikhaledi A. Synthesis and antimicrobial activity of some tetrahydro quinolone diones and pyran[2,3-d]pyrimidine derivatives. *Iran. J. Pharm. Res.* (2015) 14: 757-763.

(7) Biginelli P. Aldehyde–urea derivatives of aceto- and oxaloacetic acids. *Gazz. Chim. Ital.* (1893) 23: 360-413.

(8) Paraskar AS, Dewkar GK and Sudalai A. Cu(OTf)$_2$: A reusable catalyst for high-yield synthesis of 3, 4-dihydropyrimidin-2(1H)-ones. *Tetrahedron Lett.* (2003) 44: 3305-3308.

(9) Ma Y, Qian C, Wang L and Yang M. Lanthaneide triflate catalyzed Biginelli reaction. One-pot synthesis of dihydropyrimidinones under solvent-free conditions. *J. Org. Chem.* (2000) 65: 3864-3868.

(10) Khabazraddeh H, Tavakolinjnad Kermani E and Jaziniadad T. An efficient synthesis of 3,4-dihydropyrimidin-2(1H)-ones catalyzed by molten [Et,N][HSO$_4$]. *Arab. J. Chem.* (2012) 5: 485-488.

(11) Ramalinga R, Vijayalakshmi P and Kaimal T. N. B. Bismuth(III)-catalyzed synthesis of dihydropyrimidinones: improved protocol conditions for the Biginelli reaction. *Synlett.* (2001) 6: 863-865.

(12) Kumar KA, Kasthuraiah M, Reddy CS and Reddy CD. Mn(OAc)$_3$ • 2H$_2$O-mediated three-component, one-pot, condensation reaction: an efficient synthesis of 4-aryl-substituted 3, 4-dihydropyrimidin-2-ones. *Tetrahedron Lett.* (2001) 42: 7873-7875.

(13) Kappe CO. Highly versatile solid phase synthesis of biofunctional 4-aryl-3,4-dihydropyrimidines using resin-bound isothiourea building blocks and multidirectional resin cleavage. *Bioorg. Med. Chem. Lett.* (2001) 10: 49-51.

(14) Sabitha G, Reddy KV, Yadav JS, Shailaja D and Sivudu K. Ceria/vinylpyridine polymer nanocomposite: an ecofriendly catalyst for the synthesis of 3, 4-dihydropyrimidin-2 (1H)-ones. *Tetrahedron Lett.* (2005) 46: 8221-8224.

(15) Reddy KR, Reddy CV, Mahesh M and Raju PV. New environmentally friendly solvent free synthesis of dihydropyrimidinones catalysed by N-butyl-N,N-dimethyl-a-phenylethylammonium bromide. *Tetrahedron Lett.* (2003) 44: 8173-8175.

(16) Ahamed B, Khan R. A and Habibullah Keshari M. An improved synthesis of Biginelli-type compounds via phase-transfer catalyst. *Tetrahedron Lett.* (2009) 50: 2889-2892.

(17) Chand S, Lusunzi I, Veal DA and Williams LR. Rapid screening of the antimicrobial activity of extracts and natural products. *J. Antibiot.* (1994) 47: 1295-1304.

(18) Wayne PA. *National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Clinical and Laboratory Standards Institute (CLSI)* (2011).

This article is available online at http://www.ijpr.ir